N/A
Completed N=248
A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia
Source: ClinicalTrials.gov NCT06016556 ↗Enrolled (actual)
248
Serious AEs
0.8%
Results posted
Apr 2025
Primary outcomePrimary: Number of Participants Classified According to Education Level at Index Date — 32; 1; 22; 85 Participants
Summary
The aim of this study is to describe the baseline demographic, clinical characteristics, and Healthcare Resource Use (HCRU) of adult (≥18 years) COVID-19 patients who have been prescribed nirmatrelvir, ritonavir treatment.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Classified According to Education Level at Index Date |
32; 1; 22; 85; 0; 0 | — |
| PRIMARY Number of Participants Classified According to Employment Status at Index Date |
41; 1; 10; 42; 11; 3 | — |
| PRIMARY Height at Index Date |
1.62 | — |
| PRIMARY Weight at Index Date |
74.13 | — |
| PRIMARY Body Mass Index (BMI) at Index Date |
28.25 | — |
| PRIMARY Number of Participants Classified According to Smoking Status at Index Date |
8; 7; 207 | — |
| PRIMARY Number of Participants Who Had at Least 1 Pre-existing Comorbidity at Index Date |
224 | — |
| PRIMARY Number of Participants Who Had at Least 1 Concomitant Medication for Comorbidities at Index Date |
186 | — |
| PRIMARY Number of Participants With COVID-19 Infection During the Last 6 Months Prior to Index Date |
9 | — |
| PRIMARY Duration Between Last COVID-19 Infection and Index Date |
3.34 | — |
| PRIMARY Number of Participants Who Had Previously Received at Least 1 Dose of Any COVID-19 Vaccine |
200 | — |
| PRIMARY Number of Participants Classified According to the Type of COVID-19 Vaccine Received Previously |
1; 1; 143; 19 | — |
| PRIMARY Duration Between Previous COVID-19 Vaccination Date and Index Date |
23.16 | — |
| PRIMARY Number of Participants Classified According to Total Number of Previous COVID-19 Vaccine Doses Taken |
10; 45; 84; 7 | — |
| PRIMARY Number of Participants Classified According to Dose of Nirmatrelvir/Ritonavir Received at Index Date |
229; 19 | — |
| PRIMARY Number of Participants Classified According to Frequency of Dosing of Nirmatrelvir/Ritonavir (PAXLOVIDTM) at Index Date |
245; 2; 1 | — |
| PRIMARY Number of Participants Classified According to Dispensed Type of Nirmatrelvir/Ritonavir (PAXLOVIDTM) at Index Date |
236; 11; 1 | — |
| PRIMARY Number of Participants Classified According to Medications Used to Treat COVID-19 Infection at Index Date |
13; 11; 8; 7; 5; 3 | — |
| PRIMARY Number of Participants Who Were Hospitalized at Index Date |
120 | — |
| PRIMARY Number of Participants Who Were Hospitalized Due to COVID-19 at Index Date |
72 | — |
| PRIMARY Length of Hospitalization Stay Due to COVID-19 at Index Date |
6.64 | — |
| PRIMARY Number of Participants With Intensive Care Unit (ICU) Admission at Index Date |
17 | — |
| PRIMARY Length of ICU Stay Due to COVID-19 at Index Date |
17.83 | — |
| PRIMARY Number of Participants Who Were on Supplemental Oxygen Use at Index Date |
14 | — |
| PRIMARY Number of Participants Who Were on Vasopressor Use at Index Date |
— | — |
| PRIMARY Number of Participants With Intubation at Index Date |
2 | — |
| PRIMARY Number of Participants With Outpatient Visits at Index Date |
32 | — |
| PRIMARY Number of Participants Who Had Emergency Room (ER) Visits Due to COVID-19 at Index Date |
126 | — |
| SECONDARY Number of Participants Who Were Hospitalized During the 30-day Post-Index Period |
23 | — |
| SECONDARY Number of Participants Who Were Hospitalized Due to COVID-19 During the 30-day Post-Index Period |
2 | — |
| SECONDARY Length of Hospitalization Stay Due to COVID-19 During the 30-day Post-Index Period |
23.00 | — |
| SECONDARY Number of Participants With ICU Admission During the 30-day Post-Index Period |
9 | — |
| SECONDARY Length of ICU Stay Due to COVID-19 During the 30-day Post-Index Period |
8.00 | — |
| SECONDARY Number of Participants Who Were on Supplemental Oxygen Use During the 30-day Post-Index Period |
6 | — |
| SECONDARY Number of Participants Who Were on Vasopressor Use During the 30-day Post-Index Period |
1 | — |
| SECONDARY Number of Participants With Intubation During the 30-day Post-Index Period |
2 | — |
| SECONDARY Number of Participants Who Had Outpatient Visits During the 30-day Post-Index Period |
61 | — |
| SECONDARY Number of Participants Who Had ER Visits Due to COVID-19 During the 30-day Post-Index Period |
21 | — |
| SECONDARY Number of Participants Classified According to COVID-19 Polymerase Chain Reaction (PCR) and Antigen Test Results During the 30-day Post-Index Period |
4; 1; 7; 5 | — |
| SECONDARY Time to Negative COVID-19 Test During the 30-day Post-Index Period |
15.09 | — |
Eligibility Criteria
Inclusion Criteria
- Confirmed COVID-19 infection during the study observation period
- Nirmatrelvir, ritonavir written prescription
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT06016556). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.